Send to

Choose Destination
J Cell Physiol. 2018 Dec 4. doi: 10.1002/jcp.27776. [Epub ahead of print]

MicroRNA in leukemia: Tumor suppressors and oncogenes with prognostic potential.

Author information

Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran.
Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Borujen, Iran.
Hematology, Oncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Cell and Molecular Biology, College of Science, Kish International Campus, University of Tehran, Kish, Iran.
Department of Hematology and Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Department of Genetics, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Internal Medicine, Montefiore New Rochelle Hospital, Albert Einstein College of Medicine, New York, New York.
Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.


Leukemia is known as a progressive malignant disease, which destroys the blood-forming organs and results in adverse effects on the proliferation and development of leukocytes and their precursors in the blood and bone marrow. There are four main classes of leukemia including acute leukemia, chronic leukemia, myelogenous leukemia, and lymphocytic leukemia. Given that a variety of internal and external factors could be associated with the initiation and progression of different types of leukemia. One of the important factors is epigenetic regulators such as microRNAs (miRNAs) and long noncoding RNAs (ncRNA). MiRNAs are short ncRNAs which act as tumor suppressor (i.e., miR-15, miR-16, let-7, and miR-127) or oncogene (i.e., miR-155, miR-17-92, miR-21, miR-125b, miR-93, miR-143-p3, miR-196b, and miR-223) in leukemia. It has been shown that deregulation of these molecules are associated with the initiation and progression of leukemia. Hence, miRNAs could be used as potential therapeutic candidates in the treatment of patients with leukemia. Moreover, increasing evidence revealed that miRNAs could be used as diagnostic and prognostic biomarkers in monitoring patients in early stages of disease or after received chemotherapy regimen. It seems that identification and development of new miRNAs could pave to the way to the development new therapeutic platforms for patients with leukemia. Here, we summarized various miRNAs as tumor suppressor and oncogene which could be introduced as therapeutic targets in treatment of leukemia.


biomarker; exosome; leukemia; microRNA; oncogene; therapy; tumor suppressor


Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center